Comparative drug systemic exposure and clinical efficacy against resistant nematodes in lambs treated with different albendazole formulations.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Suárez G;Suárez G; Alvarez L; Castells D; Correa O; Fagiolino P; Lanusse C
  • Source:
    Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2011 Dec; Vol. 34 (6), pp. 557-64. Date of Electronic Publication: 2011 Mar 03.
  • Publication Type:
    Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 7910920 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2885 (Electronic) Linking ISSN: 01407783 NLM ISO Abbreviation: J Vet Pharmacol Ther Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford, Blackwell Scientific Publications.
    • Subject Terms:
      Albendazole/*pharmacokinetics ; Antinematodal Agents/*pharmacokinetics ; Haemonchiasis/*veterinary ; Sheep Diseases/*drug therapy ; Trichostrongylosis/*veterinary; Albendazole/blood ; Albendazole/therapeutic use ; Animals ; Antinematodal Agents/blood ; Antinematodal Agents/therapeutic use ; Biological Availability ; Chemistry, Pharmaceutical ; Chromatography, High Pressure Liquid ; Feces/parasitology ; Female ; Haemonchiasis/blood ; Haemonchiasis/drug therapy ; Haemonchiasis/parasitology ; Parasite Egg Count ; Sheep ; Sheep Diseases/blood ; Sheep Diseases/parasitology ; Therapeutic Equivalency ; Trichostrongylosis/blood ; Trichostrongylosis/drug therapy ; Trichostrongylosis/parasitology
    • Abstract:
      A pharmaco-parasitological assessment of four different albendazole (ABZ) formulations was carried out in lambs infected with multiple resistant gastrointestinal (GI) nematodes. The comparative drug systemic exposure profiles (ABZ sulphoxide plasma concentrations) and anthelmintic efficacies (clinical endpoint measured through the faecal nematode eggs reduction counts) were determined for a reference formulation (RF) and three different test (T1, T2, T3) generic ABZ preparations. Fifty (50) Corriedale lambs naturally infected with multiple resistant GI nematodes were allocated into five experimental groups (n = 10). Animals in each group received treatment with either the RF, one of the test ABZ formulations (5 mg/kg by the intraruminal route) or were kept as untreated control. Blood samples were collected over 48 h post-treatment. ABZ parent drug was not recovered in the bloodstream. The ABZ sulphoxide (ABZSO) and sulphone (ABZSO(2) ) metabolites were measured in plasma by ultraviolet high-performance liquid chromatography over 36-48 h post-treatment. A faecal nematode egg count reduction test (FECRT) was performed at day 10th post-treatment to lambs from all treated and untreated groups, which indicated the predominance of nematodes with high level of resistance to ABZ. Both ABZSO C(max) and AUC(0-LOQ) values obtained for the RF (pioneer product) were significantly higher (P < 0.05) than those obtained for the T1 and T3 preparations. Based on the currently available bioequivalence criteria, the test (generic) ABZ formulations under evaluation could not be considered equivalent to the RF regarding the rate (C(max) ) and extent (AUC(0-LOD) ) of drug absorption (indirectly estimated through the ABZSO metabolite). A large variation in nematode egg counts did not permit to obtain statistically significant differences among formulations. However, a favourable trend in the efficacy against the most resistant nematodes was observed for the formulations with the highest ABZSO systemic exposure.
      (© 2011 Blackwell Publishing Ltd.)
    • Accession Number:
      0 (Antinematodal Agents)
      F4216019LN (Albendazole)
    • Publication Date:
      Date Created: 20110305 Date Completed: 20120518 Latest Revision: 20131121
    • Publication Date:
      20240829
    • Accession Number:
      10.1111/j.1365-2885.2011.01274.x
    • Accession Number:
      21371047